Document Detail

Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure - a substudy to the MERIT-HF trial.
MedLine Citation:
PMID:  11511433     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Beta-blockade usually causes a slight reduction in exercise capacity among healthy subjects, while more variable results have been observed in chronic heart failure (CHF), probably related to patients studied, methods and agent used. The effect of metoprolol controlled release/extended release (CR/XL) on peak oxygen uptake (peak VO(2)) in this patient population has not previously been investigated.
AIMS: We examined the effect of long-term treatment with the selective beta(1)-receptor blocker metoprolol CR/XL once daily on exercise capacity in patients with CHF.
METHODS: Ninety-four patients (70 males and 24 females; mean age 63.6+/-10.6 years) with chronic symptomatic heart failure in New York Heart Association (NYHA) functional class II-IV, and with ejection fraction <or=40%, stabilized on optimum standard therapy were randomized to metoprolol CR/XL or placebo in a double-blind trial. Exercise capacity was evaluated by peak VO(2) at baseline, after 3 months and at the end of study (mean follow-up 11.4+/-0.4 months).
RESULTS: Compared with placebo metoprolol CR/XL produced a significant decrease in heart rate by 11 beats/min at rest and 18 beats/min at peak exercise. There was a tendency for a temporal decline in peak VO(2) after 3 months of therapy in both groups, but altogether peak VO(2) remained unchanged from baseline with no difference between the groups at 1 year.
CONCLUSIONS: In patients with moderate to severe CHF, 11.4 months of beta(1)-blockade with metoprolol CR/XL had no effect on exercise capacity when compared with placebo or baseline.
L Gullestad; C Manhenke; T Aarsland; R Skårdal; H Fagertun; J Wikstrand; J Kjekshus
Related Documents :
19218333 - Impact of exercise training on myostatin expression in the myocardium and skeletal musc...
18343723 - Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: a...
17313253 - Salivary immunoglobulin a response to a collegiate rugby game.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of heart failure     Volume:  3     ISSN:  1388-9842     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2001 Aug 
Date Detail:
Created Date:  2001-08-20     Completed Date:  2001-10-18     Revised Date:  2011-06-08    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  463-8     Citation Subset:  IM    
Department of Cardiology, Division of Heart and Lung Diseases, Rikshospitalet, 0027 Oslo, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chronic Disease
Confidence Intervals
Delayed-Action Preparations
Double-Blind Method
Drug Administration Schedule
Exercise Tolerance / drug effects*
Follow-Up Studies
Heart Failure / drug therapy*,  physiopathology
Heart Function Tests
Hemodynamics / drug effects
Long-Term Care
Metoprolol / administration & dosage*
Middle Aged
Oxygen Consumption / physiology
Reference Values
Treatment Outcome
Reg. No./Substance:
0/Delayed-Action Preparations; 37350-58-6/Metoprolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and inc...
Next Document:  Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient grou...